A PHASE IIA MULTICENTER, OPEN-LABEL, 12-WEEK STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY AND TO PROVIDE PROOF OFMECHANISM OF ALOGABAT IN CHILDREN AND ADOLESCENTS AGED 517 YEARS WITH ANGELMAN SYNDROME (AS) WITH DELETION GENOTYPE
Study of Alogabat in Children and Adolescents with Angelman Syndrome (AS)
Sponsor: F. Hoffman La Roche Ltd
Enrolling: Male and Female Patients
IRB Number: AAAU5011
Contact: Jennifer Bain: / jb3634@cumc.columbia.edu
Additional Study Information: This is a Phase IIA Multicenter, open-label, 12-week study to investigate the pharmacokinetics and safety and to provide proof of mechanism of the drug, Alogabat (RO7017773) in children and adolescents aged 5-17 years old with Angelman Syndrome with the deletion genotype.
Investigator
Jennifer Bain, MD
Do You Qualify?
Is your child between 5-17 years old? Yes No
Has your child been diagnosed with Angelman Syndrome (AS)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Jennifer Bain
jb3634@cumc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE